Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

3.0K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.0K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

3.9K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.9K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

5.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Tissues01:18

Tissues

85.6K
Cells with similar structure and function are grouped into tissues. A group of tissues with a specialized function is called an organ. There are four main types of tissue in vertebrates: epithelial, connective, muscle, and nervous.
85.6K
Tissues01:25

Tissues

68.9K
Tissues are a group of cells that share a common embryonic origin. Microscopic observation reveals that the cells in a tissue share morphological features and are arranged in an orderly pattern to perform specific functions. From an evolutionary perspective, tissues appear in more complex organisms. Although there are many types of cells in the human body, they are organized into four broad categories of tissues: epithelial, connective, muscle, and nervous. Each of these categories is...
68.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Best original research presented at the 26th European Congress on Gynaecological Oncology: Best of ESGO 2025.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.

JCO precision oncology·2025
Same author

Clearer Horizons: The latest advances in clear cell ovarian cancer treatment.

Cancer treatment reviews·2025
Same author

GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer-A Study of the GANNET53 Consortium.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Highlights from the 26th European Congress on Gynaecological Oncology in Rome: interview compilation of the ENYGO-IJGC editorial fellows.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

French screening recommendations: A systematic review

Sante publique (Vandoeuvre-les-Nancy, France)·2025
Same journal

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.

Future oncology (London, England)·2026
Same journal

Disparities in mortality among HER2-positive breast cancer patients treated with trastuzumab in Chile (2015-2024): real-world evidence from 4,920 cases.

Future oncology (London, England)·2026
Same journal

VEBrant: a multicenter, phase II study of MET inhibitor vebreltinib combined with PD-1-based immunotherapy in advanced clear cell sarcoma.

Future oncology (London, England)·2026
Same journal

Prognostic but not predictive: the clinical implications of androgen receptor expression in breast cancer patients undergoing neoadjuvant chemotherapy.

Future oncology (London, England)·2026
Same journal

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Future oncology (London, England)·2026
Same journal

The letter to editor regarding "real-world management of oral mucositis/stomatitis among patients with advanced non-small cell lung cancer (NSCLC) or breast cancer (BC)".

Future oncology (London, England)·2026
See all related articles

Related Experiment Video

Updated: Feb 10, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

Options for treating different soft tissue sarcoma subtypes.

Isabelle Ray-Coquard1, Delphine Serre1, Peter Reichardt2

  • 1GINECO/TMRO and NETSARC Network, Center Léon Bérard & Université Claude Bernard, Lyon, France.

Future Oncology (London, England)
|May 17, 2018
PubMed
Summary
This summary is machine-generated.

Soft tissue sarcoma treatment is becoming more specific to each subtype. Advanced uterine leiomyosarcoma benefits from trabectedin for long-term stabilization, while liposarcoma subtypes show varied responses to therapies.

Keywords:
alveolar soft part sarcomaangiosarcomaclear cell sarcomaliposarcomatranslocation-related sarcomasundifferentiated pleomorphic sarcomauterine leiomyosarcoma

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K

Related Experiment Videos

Last Updated: Feb 10, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.9K

Area of Science:

  • Oncology
  • Genetics
  • Pathology

Background:

  • Soft tissue sarcoma (STS) management is increasingly subtype-specific.
  • Uterine leiomyosarcoma and liposarcoma subgroups exhibit distinct characteristics.
  • Genetic insights are crucial for understanding STS pathogenesis and developing targeted therapies.

Purpose of the Study:

  • To highlight the subtype-dependent nature of soft tissue sarcoma management.
  • To review current treatment strategies for specific STS subtypes.
  • To emphasize the role of genetic analysis in advancing STS research.

Main Methods:

  • Literature review of current management strategies for soft tissue sarcomas.
  • Analysis of genetic and cytogenetic classifications of STS.
  • Examination of treatment responses across different STS subtypes.

Main Results:

  • Surgery is recommended for uterine leiomyosarcoma; trabectedin is preferred for advanced cases.
  • Liposarcoma subgroups display diverse morphologies, genetics, and treatment responses.
  • Cytogenetic analysis categorizes STS into specific translocations or chromosomal rearrangements.

Conclusions:

  • Tailored treatment approaches based on STS subtype are essential for optimal outcomes.
  • Further research is needed for rare subtypes like undifferentiated sarcomas and angiosarcomas.
  • Genetic profiling holds promise for novel therapeutic targets in soft tissue sarcoma.